Trial Profile
A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 01 Jun 2023 Planned End Date changed from 1 May 2023 to 1 May 2026.
- 01 Jun 2023 Planned primary completion date changed from 1 May 2023 to 1 May 2026.
- 01 Jun 2022 Planned End Date changed from 1 May 2022 to 1 May 2023.